Navigation Links
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels

ABBOTT PARK, Ill., Dec. 17 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V(TM) Everolimus Eluting Coronary Stent System. The 2.25 mm stent system would offer physicians an option for treating coronary artery disease in narrower vessels that is based on the proven efficacy, safety and deliverability of XIENCE V.

In July 2008, XIENCE V was launched in the United States, where it quickly became the market-leading drug eluting stent. The addition of a 2.25 mm size would complement the broad range of XIENCE V lengths and diameters. Upon U.S. Food and Drug Administration (FDA) approval of the 2.25 mm stent system, the device will be called XIENCE NANO(TM) in the United States. The XIENCE V 2.25 mm stent system received CE Mark (Conformite Europeene) approval and was launched in various countries in Europe, Asia and Latin America in March 2008.

"Treatment of lesions in small coronary vessels is often complex and associated with higher rates of complications. Being able to deliver a stent accurately to the diseased area of the vessel is crucial for successful treatment," said Marco Costa, M.D., Ph.D., director of Invasive Services, and director of the Center for Research and Innovation, Harrington-McLaughlin Heart and Vascular Institute, University Hospitals, Case Western Reserve University, and principal investigator of the SPIRIT Small Vessel trial. "Given the strong clinical performance and ease of use of XIENCE V, a smaller stent system would significantly enhance the treatment options for patients with coronary artery disease in small vessels."

The SPIRIT Small Vessel trial is designed to study 250 patients at approximately 50 centers in the United States. The primary endpoint is a composite measure of cardiac death, heart attack (target vessel myocardial infarction) and target lesion revascularization (repeat procedures on the treated vessel) at one year.

XIENCE V in Small Vessels

Observational data supporting the safety and efficacy of XIENCE V in the treatment of coronary artery disease in small vessels was presented at the 2008 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in October. James B. Hermiller, M.D., director, Cardiac Catheterization Labs, The Care Group at St. Vincent Hospital in Indianapolis, and an investigator of the SPIRIT III trial, presented subgroup data from the SPIRIT III trial comparing XIENCE V to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) in patients with small vessels. In this subgroup analysis, patients were treated with a 2.5 mm stent system and had an average reference vessel diameter of 2.36 mm.

"In the SPIRIT III subgroup analysis, XIENCE V performed extremely well in small vessels. Compared to TAXUS, XIENCE V reduced in-stent late loss, or vessel re-narrowing, by 80 percent eight months after the procedure, and reduced major adverse cardiac events by 74 percent at nine months," said Dr. Hermiller. "When you consider these trends, the availability of a smaller XIENCE V stent system specifically designed to treat lesions in small vessels has the potential to significantly improve patient care."

The SPIRIT III small vessel subgroup analysis demonstrated the following key results for XIENCE V:

-- An observed 80 percent reduction in in-stent late loss compared to TAXUS at eight months (0.11 mm for XIENCE V vs. 0.54 mm for TAXUS, p-value=0.011)*.

-- An observed 74 percent reduction in major adverse cardiac events (MACE) compared to TAXUS at nine months (3.2 percent for XIENCE V vs. 12.5 percent for TAXUS, p-value=0.017)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (TLR driven by lack of blood supply).

-- An observed 68 percent reduction in the risk of target vessel failure (TVF, cardiac events related to the treated vessel) compared to TAXUS at nine months (5.2 percent for XIENCE V vs. 16.1 percent for TAXUS, p-value=0.019)*. TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).

-- An observed 90 percent reduction in target lesion revascularization (TLR) compared to TAXUS at nine months (1.3 percent for XIENCE V vs. 12.5 percent for TAXUS, p-value=0.002)*.


The XIENCE V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

Long-term results with XIENCE V in the SPIRIT III pivotal U.S. clinical trial demonstrated a 45 percent reduction in the risk of MACE compared to TAXUS at two years. XIENCE V demonstrated a 32 percent reduction in TVF compared to TAXUS at two years. XIENCE V also demonstrated a low rate of stent thrombosis between one and two years, defined as very late stent thrombosis, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.3 percent for XIENCE V and 1.0 percent for TAXUS). XIENCE V met its primary endpoint in the SPIRIT III clinical trial with a statistically significant 50 percent reduction in in-segment late loss (vessel renarrowing) at eight months compared to TAXUS.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was approved by the FDA in July 2008 and launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott supplies a private-labeled XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

* P-values are for descriptive purposes only.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
(Date:10/10/2015)... ... ... have to walk with crutches for the rest of my life," said an inventor from ... that would give me more independence and freedom would be amazing. This inspired me to ... developed the STRAP IN to enable an individual to walk with crutches without having to ...
(Date:10/10/2015)... ... , ... The Bank of America 500 NASCAR Sprint Cup Series race is ... defending race winner, Kevin Harvick, will battle it out for the checkered flag with ... the stars of the NASCAR Sprint Cup Series. As part of the opening ...
(Date:10/10/2015)... ... October 10, 2015 , ... Attending medical school and ... men, women and children. Depending on the school, the exact details of the ... field. , Students in a medical school must complete undergraduate classwork and requirements ...
(Date:10/10/2015)... PA (PRWEB) , ... October 10, 2015 , ... ... Wigrizer, Brecher & Miller is pleased to be recognized by The National Law ... This list acknowledges the 50 law firms across the United States who obtained ...
(Date:10/9/2015)... ... October 09, 2015 , ... Doctors on Liens ... in Fresno , to provide highly needed medical care to personal injury victims. ... medical providers to diagnose, document and treat the variety of conditions ailing them. ...
Breaking Medicine News(10 mins):
... Calif., Sept. 8 (Nasdaq: WHRTD ) - World ... the Company received a NASDAQ Staff Deficiency Letter indicating that the ... This rule requires the Company to maintain a minimum of 500,000 ... Subsequently on September 4, 2009, the Company received a letter from ...
... , WESTON, Fla., Sept. 8 Kidz-Med ... today announced the receipt of a follow-up purchase order of equal ... and closed a large purchase of Kidz-Med,s ... Company,s history. , , Dr. Christopher ...
... , Expanding facility will provide training ... the Highbridge area of the Bronx , , ... officially open the newest addition to the non-profit agency on September ... cutting ceremony at the facility. Located at 1438 Ogden Ave., ...
... NEW YORK, NY, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: ... company that identifies, acquires, and develops novel drug ... today announced it has appointed Dr. Anders Boegh ... Dr. Boegh Jensen will contribute his considerable expertise ...
... results for recipients in study , TUESDAY, Sept. 8 ... organ donors may help preserve the quality of their ... Most transplanted kidneys come from donors whose hearts are ... chain of events that can damage organs and increase ...
... Ohio Hairstylists may have a unique opportunity to ... according to a small, exploratory study. More than ... older clients often or always shared their problems during ... to notice when their older clients are starting to ...
Cached Medicine News:
(Date:10/9/2015)... 2015 Eli Lilly and Company (NYSE: LLY ... approximately 50 new jobs to its research and development presence ... York, New York . --> ... will include a translational immuno-oncology hub and a Lilly "portal," ... access to cutting-edge drug discovery capabilities, including chemistry and lead ...
(Date:10/9/2015)... 2015 Ansun BioPharma announced a presentation at ... ) regarding the compassionate use of DAS181 under an ... who was co-infected with influenza and parainfluenza (Abstract # ... O 2 requirement was reduced and the patient,s ... go off the respirator on day 5. Between day ...
(Date:10/9/2015)... El ,JCA-Mauvernay Award 2015, se ha otorgado a los ... Junko Takita    --> El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... a los doctores Yutaka Kondo y ... global con sede enSuiza, presentará el ,JCA-Mauvernay Award, el 10 de octubre a ...
Breaking Medicine Technology:
... AstraZeneca (NYSE:,AZN) today announced that it submitted ... Food and Drug Administration (FDA) for approval of ... for the treatment of patients with Chronic Obstructive,Pulmonary ... long-term,maintenance treatment of asthma in patients 12 years ...
... Inc. ("QI"),announces the commencement of a Phase I/II ... a novel anti-cancer vaccine/immunotherapy that will,be used on ... accepted,into the study have previously failed to respond ... QI has commissioned,the study to be done by ...
Cached Medicine Technology:
... ideal where space is restricted. Due to ... and flexible in every situation. For many ... be positioned optimally on the JUPITER during ... the operating theatre, the high level of ...
... schaerer axis 800 operating ... designed for those disciplines ... access. The stability, the ... the offset positioned telescoping ...
... words "mobile operating table" literally! The Alphastar 1132 ... of a general purpose operating table - is ... operations, a cable connected hand control, an IR-hand ... there is a control panel at the top ...
... introduce the Cmax operating table that combines ... surgical table with the radiolucence and precise ... the most advanced, versatile surgical table on ... to support advancements in surgical procedures and ...
Medicine Products: